Mucus and ALI models of the human intestine

Active Project Grant Awarded Last action

Award ID
R44DK130708
Recipient
Awarding agency
Obligated
$1,837,122

Award facts

Completion date 92% complete
Place of performance
North Carolina, USA

Award details come from USAspending.gov.

Description

Abstract
The mucus layer is the first line of defense against infiltration of microorganisms, digestive enzymes and acids, digested food particles, microbial by-products, and food-associated toxins. This layer coats the interior surface of the GI tract, lubricates luminal contents and acts as a physical barrier to bacteria and other antigenic substances present in the lumen. The moist, nutrient-rich mucus layer adjacent to the epithelial barrier of the GI tract is also essential in the maintenance of intestinal homeostasis and contains a thriving biofilm including beneficial and pathogenic microbial populations. However, mucus has proven difficult to study, owing to IT compositional and functional complexity and a substantial lack of either high-quality purified samples or cell- based culture systems containing mucus. This project will establish a gastrointestinal (GI) model for both harvesting physiologically relevant mucus and an epithelial culture system that possesses a native mucus layer. Building on altis' capabilities to generate models with greater physiological relevance using donor-derived cells, this program will establish key protocols and workflows to ensure a reliable and reproducible mucus layer to additionally replicate in vivo GI morphology and function. In aim 1, we will commercially manufacture pure, native, sterile human GI mucus from cultures of human small and large intestine. In aim 2, we will establish a novel commercial air-liquid interface model of human primary GI epithelia and demonstrate applications relevant to GI drug absorption and metabolism. Based on prior discussions with our pharmaceutical development customers, we view the commercial potential for this model as strong, especially given the unique capabilities of altis' current platform.

Transactions

Action Obligated Date
Amendment $1,001,183
Amendment $0
Original award $835,939

Quick answers

Who received award R44DK130708?

R44DK130708 was awarded to Altis Biosystems, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on June 9, 2025.

How much is award R44DK130708 worth?

$1,837,122 has been obligated on R44DK130708.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award